financetom
Business
financetom
/
Business
/
BRIEF-Seven & I Holdings Co Ltd: Notice Regarding Completion Of Acquisition Of Part Of Business From U.S. Company Sunoco LP By A Consolidated Subsidiary
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
BRIEF-Seven & I Holdings Co Ltd: Notice Regarding Completion Of Acquisition Of Part Of Business From U.S. Company Sunoco LP By A Consolidated Subsidiary
Apr 16, 2024 4:39 PM

April 17 (Reuters) - Seven & i Holdings Co Ltd ( SVNDF ):

* SEVEN & I HOLDINGS CO LTD ( SVNDF ) - NOTICE REGARDING COMPLETION OF

ACQUISITION OF PART OF BUSINESS FROM U.S. COMPANY SUNOCO LP BY A

CONSOLIDATED SUBSIDIARY

Source text for Eikon:

Further company coverage:

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Microsoft Cloud Business Faces Legal Action in South Africa for Anticompetitive Practices
Market Chatter: Microsoft Cloud Business Faces Legal Action in South Africa for Anticompetitive Practices
Apr 4, 2024
02:11 PM EDT, 04/04/2024 (MT Newswires) -- Microsoft ( MSFT ) is likely to be charged by regulators in South Africa for squeezing out its competition by making it difficult for local vendors to transition their cloud licenses, Bloomberg reported Thursday, citing people with the knowledge of the matter. The South African Competition Commission is looking to file a formal...
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial
ADC Therapeutics Shares Rise After Completion of Dose Escalation Part of Phase 1b Lymphoma Trial
Apr 4, 2024
02:12 PM EDT, 04/04/2024 (MT Newswires) -- ADC Therapeutics ( ADCT ) rose past 10% in recent Thursday trading after the company said it completed dose escalation in its phase 1b trial of Zynlonta plus glofitamab or mosunetuzumab in patients with relapsed/refractory B-cell non-hodgkin lymphoma. There were no dose-limiting toxicities, no or low-grade cytokine release syndrome, and no immune effector...
Drilling Deep: Analyst Outlines Chesapeake Merger Synergies, Delays Due To Regulatory Risks
Drilling Deep: Analyst Outlines Chesapeake Merger Synergies, Delays Due To Regulatory Risks
Apr 4, 2024
Keybanc Capital Market analyst Tim Rezvan initiated coverage on Chesapeake Energy Corporation ( CHK )  at Sector Weight rating. The rating reflects the near/medium-term outlook for natural gas. The analyst says management is acting prudently by curtailing production amid weak prices.  The analyst writes that significant synergies can be extracted from the Southwestern merger and believes management is proving to be a first-mover with its push...
From Mouse To Marvel: Disney Stock Rockets 50% As CEO Bob Iger Attempts Turnaround Plan
From Mouse To Marvel: Disney Stock Rockets 50% As CEO Bob Iger Attempts Turnaround Plan
Apr 4, 2024
The Walt Disney Co ( DIS ) stock has been on a tear the past six months. The stock has returned over 50% to investors, as CEO Bob Iger‘s turnaround plans take the desired effect. So far in 2024, it’s up over 32.50%. Disney ( DIS ) stock momentum is due to several catalysts, including: The company’s strong financial performance...
Copyright 2023-2026 - www.financetom.com All Rights Reserved